The Journal of the Korean Rheumatism Association 2008; 15(3): 204-211
Published online September 30, 2008
© Korean College of Rheumatology
이유현1ㆍ이지수2ㆍ강은숙3
홍익병원 류마티스내과1, 이화여자대학교 의학전문대학원 류마티스내과2, 삼성서울병원 진단검사의학과3
Correspondence to : Jisoo Lee
Objective: To define the state of remission based on American College of Rheumatology (ACR) preliminary criteria in Korean patients with rheumatoid arthritis (RA). Methods: A hundred three patients of RA, followed up over 1 year, were selected at Ewha medical center from May 2000 to May 2006. Remission was defined by ACR preliminary criteria. Data were obtained from the initial and the last visit. Data on initial tender joint count (TJC) and swollen joint count (SJC), treatment, disease duration, remission duration were collected. Initial ESR, CRP, rheumatoid factor (RF), TJC and SJC were also performed at the last clinical visit or at the time of remission. Results: Patients in remission were 35%. The maintenance duration of remission was 4.8±9.0 (mean±SD) months. Remission group had shorter disease duration (20.2±34.7 vs. 58.2±83.2 months, p=0.010), were at earlier stage of the disease (<2 years of symptom onset) (80.6 vs. 52.2%, p=0.006) compared to non-remission group. Percentage of patients showing decrease in RF titer was significantly higher in the remission group compared to the non-remission group (p=0.049). However, seronegative conversion of RF was not related to remission status (15.6 vs. 14.8%). In the non-remission group, pain was the most persistently non-satisfying clinical variable of the ACR preliminary criteria. Conclusion: Patients at early stage of disease achieved clinical remission in higher rate. Changes of RF titer was affected by clinical remission status.
Keywords Rheumatoid arthritis, Remission, Criteria
The Journal of the Korean Rheumatism Association 2008; 15(3): 204-211
Published online September 30, 2008
Copyright © Korean College of Rheumatology.
이유현1ㆍ이지수2ㆍ강은숙3
홍익병원 류마티스내과1, 이화여자대학교 의학전문대학원 류마티스내과2, 삼성서울병원 진단검사의학과3
You-Hyun Lee1, Jisoo Lee2, Eun-Sook Kang3
Department of Rheumatology, Hongik Hospital1, Department of Rheumatology, Ewha Womans University Mokdong Hospital2, Department of Laboratory Medicine, Samsung Medical Center3, Seoul, Korea
Correspondence to:Jisoo Lee
Objective: To define the state of remission based on American College of Rheumatology (ACR) preliminary criteria in Korean patients with rheumatoid arthritis (RA). Methods: A hundred three patients of RA, followed up over 1 year, were selected at Ewha medical center from May 2000 to May 2006. Remission was defined by ACR preliminary criteria. Data were obtained from the initial and the last visit. Data on initial tender joint count (TJC) and swollen joint count (SJC), treatment, disease duration, remission duration were collected. Initial ESR, CRP, rheumatoid factor (RF), TJC and SJC were also performed at the last clinical visit or at the time of remission. Results: Patients in remission were 35%. The maintenance duration of remission was 4.8±9.0 (mean±SD) months. Remission group had shorter disease duration (20.2±34.7 vs. 58.2±83.2 months, p=0.010), were at earlier stage of the disease (<2 years of symptom onset) (80.6 vs. 52.2%, p=0.006) compared to non-remission group. Percentage of patients showing decrease in RF titer was significantly higher in the remission group compared to the non-remission group (p=0.049). However, seronegative conversion of RF was not related to remission status (15.6 vs. 14.8%). In the non-remission group, pain was the most persistently non-satisfying clinical variable of the ACR preliminary criteria. Conclusion: Patients at early stage of disease achieved clinical remission in higher rate. Changes of RF titer was affected by clinical remission status.
Keywords: Rheumatoid arthritis, Remission, Criteria
Bon San Koo, Seokchan Hong, You Jae Kim, Yong-Gil Kim, Chang-Keun Lee, Bin Yoo
J Rheum Dis 2014; 21(1): 20-24Byeongzu Ghang, M.D., Ph.D., Jin Kyun Park, M.D., Ph.D., Ji Hyeon Ju, M.D., Ph.D., Seungwoo Han, M.D., Ph.D.
J Rheum Dis -0001; ():Shohei Anno, M.D., Kentaro Inui, M.D., Ph.D., Masahiro Tada, M.D., Ph.D., Yuko Sugioka, M.D., Ph.D., Tadashi Okano, M.D., Ph.D.,, Kenji Mamoto, M.D., Ph.D., Tatsuya Koike, M.D., Ph.D.
J Rheum Dis -0001; ():